Ascendis Pharma A/S: 5%+ holders

As of November 4, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Ascendis Pharma A/S. The largest reported stake is T. Rowe Price Investment Management, Inc.'s, at 10.5%. 13 filings are on record since August 13, 2025 (Schedule 13G/A, May 7, 2026).

Sell to companies like Ascendis Pharma A/S? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-13 · Reporting person: Artisan Partners Asset Management Inc. · Sole voting: 0 · Shared voting: 2,422,862 · Sole dispositive: 0 · Shared dispositive: 2,634,024 · SCHEDULE 13G/A, 2026-08-13
• Filed 2026-05-15 · Holder: Janus Henderson Group Plc · Percent: 6% · SCHEDULE 13G/A
• Filed 2026-05-14 · Holder: Capital International Investors · Percent: 3.2% · SCHEDULE 13G/A
• Filed 2026-05-07 · Holder: T. Rowe Price Investment Management, Inc. · Percent: 9.9% · SCHEDULE 13G
• Filed 2026-05-07 · Holder: T. Rowe Price Investment Management, Inc. · Percent: 10.5% · SCHEDULE 13G/A

Ascendis Pharma A/S has 13 Schedule 13D or 13G filings on record since 2025-08-13. 4 holders' latest filing reports 5% or more of ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Ascendis Pharma A/S and the warning signs.

See Ascendis Pharma A/S' free Snapshot Watch Ascendis Pharma A/S: email me the next time it files something

Free to see. No signup.

Want the whole picture on Ascendis Pharma A/S?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Ascendis Pharma A/S: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Ascendis Pharma A/S covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Ascendis Pharma A/S by CUSIP K08588103 and gives its principal executive office as Tuborg Boulevard 12, Hellerup (SCHEDULE 13G/A, 2026-08-13).

Timeline

Swipe the table sideways to see every column.

Questions about who owns Ascendis Pharma A/S

Who owns Ascendis Pharma A/S?

On this page, 4 holders' latest ownership filings report 5% or more of Ascendis Pharma A/S: T. Rowe Price Investment Management, Inc. (10.5%, Schedule 13G/A, filed 2026-05-07), Westfield Capital Management Company, L.P. (8.48%, Schedule 13G/A, filed 2026-02-11), Fmr LLC (6.6%, Schedule 13G/A, filed 2026-05-06) and Janus Henderson Group Plc (6%, Schedule 13G/A, filed 2026-05-15).

Who are the largest shareholders of Ascendis Pharma A/S?

By the share each holder's latest filing reports, the largest holders of Ascendis Pharma A/S on this page are T. Rowe Price Investment Management, Inc. (10.5%), Westfield Capital Management Company, L.P. (8.48%) and Fmr LLC (6.6%).

When did T. Rowe Price Investment Management, Inc. buy into Ascendis Pharma A/S?

The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Investment Management, Inc. on this page is the Schedule 13G/A, filed 2025-08-14, reporting 6.4%; its latest, Schedule 13G/A filed 2026-05-07, reports 10.5%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Ascendis Pharma A/S. With no account yet, you sign up free and land on the result.

• Get an alert when Ascendis Pharma A/S is mentioned again
• Find former Ascendis Pharma A/S employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes